Business Description
Herantis Pharma PLC
ISIN : FI4000087861
Total Employee Number:
13Compare
Compare
Traded in other countries / regions
HRTIS.Finland IPO Date
2014-06-11Description
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinsons disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 104.64 | |||||
Equity-to-Asset | -0.63 | |||||
Debt-to-Equity | -0.02 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.3 | |||||
3-Year EPS without NRI Growth Rate | 24.1 | |||||
3-Year FCF Growth Rate | 24.9 | |||||
3-Year Book Growth Rate | -159.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.67 | |||||
9-Day RSI | 53.28 | |||||
14-Day RSI | 47.34 | |||||
3-1 Month Momentum % | 1.13 | |||||
6-1 Month Momentum % | -22.84 | |||||
12-1 Month Momentum % | -3.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | -12.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -191.87 | |||||
ROIC % | -1713.21 | |||||
3-Year ROIIC % | -221.19 | |||||
ROCE % | -229.93 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 163 | |||||
PE Ratio without NRI | 163 | |||||
EV-to-EBIT | -6.49 | |||||
EV-to-EBITDA | -6.49 | |||||
EV-to-FCF | -6.56 | |||||
Earnings Yield (Greenblatt) % | -15.42 | |||||
FCF Yield % | -14.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Herantis Pharma PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0.01 | ||
| Beta | 1.0683 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.24 | ||
| Volatility % | 51.12 | ||
| 14-Day RSI | 47.34 | ||
| 14-Day ATR (€) | 0.098389 | ||
| 20-Day SMA (€) | 1.6178 | ||
| 12-1 Month Momentum % | -3.76 | ||
| 52-Week Range (€) | 1.44 - 3.87 | ||
| Shares Outstanding (Mil) | 26.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Herantis Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Herantis Pharma PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 12 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 12 days | ||
| Investor Day | 2026-05-25 | 1.77 (-0.45%) | ||
| General meeting for 2025 | 2026-04-23 14:00 | 1.70 (-0.12%) | ||
| Annual report for 2025 | 2026-03-30 | 1.66 (-0.90%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 10:00 | 2.08 (+0.48%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 2.08 (+0.48%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-21 09:00 | 1.70 (-10.76%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 1.70 (-10.76%) | ||
| General meeting for 2024 | 2025-04-24 13:00 | 1.45 (+0.00%) |
Show
Entries
Herantis Pharma PLC Frequently Asked Questions
What is Herantis Pharma PLC(OHEL:HRTIS)'s stock price today?
The current price of OHEL:HRTIS is €1.63. The 52 week high of OHEL:HRTIS is €3.87 and 52 week low is €1.44.
When is next earnings date of Herantis Pharma PLC(OHEL:HRTIS)?
The next earnings date of Herantis Pharma PLC(OHEL:HRTIS) is 2026-08-20.
Does Herantis Pharma PLC(OHEL:HRTIS) pay dividends? If so, how much?
Herantis Pharma PLC(OHEL:HRTIS) does not pay dividend.
Press Release
Articles on Herantis Pharma PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers